Profile data is unavailable for this security.
About the company
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
- Revenue in USD (TTM)0.00
- Net income in USD-5.17m
- Incorporated2021
- Employees7.00
- LocationConduit Pharmaceuticals Inc4995 Murphy Canyon Road, Suite 300SAN DIEGO 92123United StatesUSA
- Phone+1 (760) 471-8536
- Fax+1 (302) 655-5049
- Websitehttps://www.conduitpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioRestorative Therapies Inc | 174.10k | -8.00m | 11.49m | 11.00 | -- | 1.07 | -- | 65.98 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
Inhibitor Therapeutics Inc | 0.00 | -3.02m | 12.25m | 3.00 | -- | 2.96 | -- | -- | -0.0175 | -0.0175 | 0.00 | 0.024 | 0.00 | -- | -- | 0.00 | -34.83 | 27.48 | -34.99 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
Sensei Biotherapeutics Inc | 0.00 | -29.67m | 12.32m | 28.00 | -- | 0.2359 | -- | -- | -1.18 | -1.18 | 0.00 | 2.08 | 0.00 | -- | -- | 0.00 | -39.73 | -47.03 | -42.67 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0232 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Tenax Therapeutics Inc | 0.00 | -12.57m | 12.34m | 5.00 | -- | 0.7987 | -- | -- | -22.35 | -22.35 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -101.95 | -199.16 | -113.79 | -285.64 | -- | -- | -- | -- | -- | -95.94 | 0.0305 | -- | -- | -- | 30.21 | -- | -- | -- |
Conduit Pharmaceuticals Inc | 0.00 | -5.17m | 12.84m | 7.00 | -- | -- | -- | -- | -0.0667 | -0.0667 | 0.00 | -0.0738 | 0.00 | -- | -- | 0.00 | -312.39 | -- | -- | -- | -- | -- | -- | -- | -- | -21.32 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
Dominari Holdings Inc | 9.51m | -22.02m | 13.05m | 26.00 | -- | 0.3066 | -- | 1.37 | -3.85 | -3.85 | 1.67 | 6.78 | 0.1629 | -- | 2.60 | 365,730.80 | -37.71 | -26.82 | -39.96 | -27.45 | -- | -- | -231.55 | -3,353.52 | -- | -5.05 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
Yubo International Biotech Ltd | 454.29k | -1.42m | 13.18m | 18.00 | -- | -- | -- | 29.01 | -0.0118 | -0.0118 | 0.0038 | -0.0211 | 0.2462 | 0.5986 | 3.49 | 25,238.33 | -82.33 | -- | -- | -- | 80.30 | -- | -334.36 | -- | 0.1707 | -4,795.69 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
Aspira Women's Health Inc | 8.92m | -15.95m | 13.43m | 64.00 | -- | -- | -- | 1.50 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
Edesa Biotech Inc | 0.00 | -6.93m | 14.13m | 16.00 | -- | 4.93 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
Alterola Biotech Inc | 0.00 | -2.06m | 14.30m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
Senti Biosciences Inc | 338.00k | -78.62m | 14.34m | 48.00 | -- | 0.3244 | -- | 42.44 | -17.52 | -12.65 | 0.0749 | 9.66 | 0.0029 | -- | 1.12 | 7,041.67 | -68.20 | -- | -74.50 | -- | -- | -- | -23,259.47 | -- | -- | -- | 0.0023 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
Curative Biotechnology Inc | 0.00 | -6.02m | 14.41m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
Apollomics Inc | 0.00 | -57.11m | 14.46m | 45.00 | -- | 0.695 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Barclays Bank Plc (Private Banking)as of 30 Jun 2024 | 812.21k | 0.85% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 592.41k | 0.62% |
Geode Capital Management LLCas of 30 Jun 2024 | 409.43k | 0.43% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 309.18k | 0.32% |
New York State Common Retirement Fundas of 30 Jun 2024 | 98.10k | 0.10% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 84.85k | 0.09% |
Marshall Wace LLPas of 30 Jun 2024 | 59.73k | 0.06% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 56.73k | 0.06% |
Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 53.11k | 0.06% |
BlackRock Investment Management LLCas of 30 Jun 2024 | 48.70k | 0.05% |